A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine

COVID-19 Clinical Trial

Official title:

A Randomized, Double-blind, Positive-controlled Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SCTV01E (A COVID-19 Alpha/Beta/Delta/Omicron Variants S-Trimer Vaccine) in Population Aged ≥18 Years Previously Fully Vaccinated With mRNA COVID-19 Vaccine

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05238441
• Other study ID #: SCTV01E-01-mRNA-JOR-1
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 20, 2022
• Est. completion date: May 1, 2023

Study information

• Verified date: February 2022
• Source: Sinocelltech Ltd.
• Contact: Zibin Luo
• Phone: +86 13751891764
• Email: zibin_luo[@]sinocelltech.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of this study is to evaluate the immunogenicity and safety of SCTV01E in participants aged ≥18 years and previously fully immunized with mRNA COVID-19 vaccine.

Description:

The study is a randomized, double-blind, and positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E as booster compared with Comirnaty. The study is a randomized, double-blind, and positive-controlled Phase II booster study. It will evaluate the immunogenicity and safety of SCTV01E as booster compared with Comirnaty (the COVID-19 vaccine from Pfizer-BioNTech).

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 360
• Est. completion date: May 1, 2023
• Est. primary completion date: June 1, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female aged =18 years old when signing ICF;

2. Participants who were fully vaccinated with 2 doses of mRNA COVID-19 vaccine (Comirnaty from Pfizer or mRNA-1273 from Moderna) and the interval between the last dose and this study vaccination is =3 months and =12 months.

3. The participant can sign the written ICF (by applying his / her signature or fingerprint "for illiterate subject"), and can fully understand the trial procedure, the risk of participating in the trial, and other interventions that can be selected if they do not participate in the trial;

4. The participant and/or his entrusted person have the ability to read, understand, and fill in record cards;

5. Healthy participants or participants with pre-existing medical conditions who are in stable condition. The "pre-existing medical conditions" include but not limited to hypertension, diabetes, chronic cholecystitis and cholelithiasis, chronic gastritis that meet the described criteria. A stable medical condition is defined as disease not requiring significant change in therapy or no need for hospitalization as a consequence of worsening disease state for at least 3 months prior to enrollment;

6. Fertile men and women of childbearing potential voluntarily agree to take effective contraceptive measures from signing ICF to 6 months after the 1st study vaccination; the pregnancy test results of women of childbearing potential are negative on screening.

Exclusion Criteria:

1. Previously diagnosed with COVID-19;

2. A positive result of nucleic acid test for SARS-CoV-2 during the screening period;

3. Presence of fever within 3 days before the study vaccination;

4. A history of infection or disease related to severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), or other disease corresponding use of immunosuppressants;

5. A history of allergic reactions to any vaccine or drug, such as allergy, urticaria, severe skin eczema, dyspnea, laryngeal edema, and angioneurotic edema;

6. A medical or family history of seizure, epilepsy, encephalopathy and psychosis;

7. Immunocompromised patients suffering from immunodeficiency diseases, important organ diseases, immune diseases (including Guillain-Barre Syndrome [GBS], systemic lupus erythematosus, rheumatoid arthritis, asplenia or splenectomy caused by any circumstances, and other immune diseases that may have an impact on immune response in the investigator's opinion), etc.;

8. Long-term use of immunosuppressant therapy or immunomodulatory drugs for =14 days within the first six months prior to enrollment. Whereas short-term (=14 days) use of oral, inhaled and topical steroids are allowed;

9. Patients on antituberculosis therapy;

10. Presence of severe or uncontrollable cardiovascular diseases, or severe or uncontrollable disorders related to endocrine system, blood and lymphatic system, liver and kidney, respiratory system, metabolic and skeletal systems, or malignancies (skin basal cell carcinoma and carcinoma in-situ of cervix are exceptions and will not be excluded), such as severe heart failure, severe pulmonary heart disease, unstable angina, liver failure, or uremia;

11. Contraindications for intramuscular injection or intravenous blood sampling, including thrombocytopenia and other blood coagulation disorders;

12. Participants who received any immunoglobulin or blood products in the previous 3 months before enrollment, or plan to receive similar products during the study;

13. Participants who received other investigational drugs within 1 month before the study vaccination;

14. Participants who is at the acute state of disease, such as acute onset of chronic heart failure, acute sore throat, hypertensive encephalopathy, acute pneumonia, acute renal insufficiency, acute cholecystitis;

15. Participants received other drugs or vaccines used to prevent COVID-19, but participants previously received Comirnaty from Pfizer or mRNA-1273 from Moderna will not be excluded;

16. Participants vaccinated with influenza vaccine within 14 days or with other vaccines within 28 days before the study vaccination;

17. Those who donated blood or had blood loss (=450 mL) within 3 months before the vaccination or plan to donate blood during the study period;

18. Those who are pregnant or breast-feeding or plan to be pregnant during the study period;

19. Those who plan to donate ovum or sperms during the study period;

20. Those who cannot follow the trial procedures, or cannot cooperate to complete the study due to planned relocation or long-term outing;

21. Those unsuitable for participating in the clinical trial as determined by the investigator because of other abnormalities that are likely to confuse the study results, or non-conformance with the maximal benefits of the participants;

22. Those who are tested positive for HIV in terms of serology.

Related Conditions & MeSH terms

• COVID-19
• Sars-CoV-2 Infection

Intervention

Biological:
• SCTV01E
D0; intramuscular injection
• Comirnaty
D0; intramuscular injection
• SCTV01E
D180; intramuscular injection
• Comirnaty
D180; intramuscular injection

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Sinocelltech Ltd.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	GMT of neutralizing antibodies against Delta (B.1.617.2) variant on D28.		Day 28 after the study vaccination
Primary	GMT of neutralizing antibodies against Delta (B.1.617.2) variant on D208.		Day 208 after the study vaccination
Secondary	GMT of neutralizing antibodies against Omicron (B.1.1.529) variant on D28.		Day 28 after the study vaccination
Secondary	GMT of neutralizing antibodies against Omicron (B.1.1.529) variant on D208.		Day 208 after the study vaccination
Secondary	Number of IFN-? positive (characterizing Th1) and IL-4 positive (characterizing Th2) T cell subsets on D28 and D208.		Day 28 and Day 208 after the study vaccination
Secondary	Seroresponse rates of neutralizing antibodies of Delta variant from on D28.		Day 28 after the study vaccination
Secondary	Seroresponse rates of neutralizing antibodies of Omicron variant from on D28.		Day 28 after the study vaccination
Secondary	Seroresponse rates of neutralizing antibodies of Delta variant from on D208.		Day 208 after the study vaccination
Secondary	Seroresponse rates of neutralizing antibodies of Omicron variant from on D208.		Day 208 after the study vaccination
Secondary	Incidence and severity of solicited AEs of SCTV01E from D0 to D7 and D180 to D187.		Day 0 to Day 7 and Day 180 to Day 187 after the study vaccination
Secondary	Incidence and severity of all unsolicited AEs of SCTV01E from D0 to D28 and D180 to D208.		Day 0 to Day 287 and Day 180 to Day 208 after the study vaccination
Secondary	Incidence and severity of SAEs and AESIs of SCTV01E within 365 days.		Day 365 after the study vaccination